CDK4 and ovarian carcinoma: Recently, Gao et al. reported that inhibition of CDK4 by palbociclib resensitized both Rb-positive and Rb-negative MDR ovarian cancer cells with paclitaxel by increasing apoptosis (Gao et al., 2017).